Article Details
Retrieved on: 2024-02-07 19:58:45
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Amgen's experimental obesity drug AMG 133, a GLP-1 receptor agonist, and its potential in biopharma competition against GLP-1 drugs like Wegovy and Zepbound for peptide therapeutic applications.
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here